Use of coenzyme Q10 formulations in the treatment and prevention of epidermolysis bullosa

1. A method of treating Epidermolysis Bullosa (EB) in a subject having one or more wounds associated with the EB between 2.5 cm 2 and 50 cm 2 in size, the method comprising topically administering a pharmaceutical composition comprising Coenzyme Q10 (CoQ10) to the subject at a dosage of CoQ10 of at least 0.01 mg/cm 2 , thereby reducing the size of the one or more wounds associated with the EB.

2. The method of claim 1 , wherein the Epidermolysis Bullosa is Epidermolysis Bullosa Simplex, Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, or Kindler's Syndrome.

3. The method of any one of the preceding claims, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration from about one week to about twelve weeks.

4. The method of claim 1 or 2 , wherein the pharmaceutical composition comprising CoQ10 is administered to the subject from 1 to about 14 times per week for the treatment duration.

5. The method of claim 1 , wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about twice a day, for the treatment duration.

6. The method of claim 1 , wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about once a day, for the treatment duration.

7. The method of claim 1 , wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about once every two days, for the treatment duration.

8. The method of claim 1 , wherein administration of the pharmaceutical composition comprising CoQ10 to an affected area containing at least one wound for a treatment duration of about four weeks results in at least 70% reduction in the size of the affected area containing at least one wound.

9. The method of claim 1 , wherein the pharmaceutical composition comprising CoQ10 contains from about 1% to about 5% CoQ10 (w/w).

10. The method of claim 1 , wherein the pharmaceutical composition comprising CoQ10 contains about 3% CoQ10 (w/w).

11. The method of claim 1 , wherein administration of the pharmaceutical composition comprising CoQ10 to the subject results in one or more additional beneficial effects selected from the group consisting of:

a. Reduction in pain associated with the EB;

b. Reduction in inflammation associated with the EB;

c. Reduction in the number of wounds associated with the EB;

d. Increase in the rate of healing of one or more wounds associated with the EB;

e. Increase in the structural integrity of the skin of the subject suffering from EB;

f. Reduction in the number of skin infections associated with EB;

g. Increase in wound closure of wounds associated with EB;

h. Increase in re-epithelization of wounds associated with EB;

i. Increase in granulation of wounds associated with EB;

j. Reduction in an epidermal gap distance of a wound associated with EB;

k. Reduction in time for wound healing associated with EB;

l. Reduction in the amount of concomitant medications administered to the subject in order to treat the subject's EB;

m. Reduction in scarring associated with EB;

n. Increase in keratinocyte production in the skin of the subject; and

o. Increase in fibroblast production in the skin of the subject.

12. The method of claim 1 , wherein treatment of the subject results in the reduction of size of one or more wounds by at least about 70% after administration of an effective amount of CoQ10 for a treatment duration of about four weeks.

13. The method of claim 12 , wherein the pharmaceutical composition comprising CoQ10 contains from about 1% to about 5% CoQ10 (w/w).

14. The method of claim 12 , wherein the pharmaceutical composition comprising CoQ10 contains about 3% CoQ10 (w/w).

15. The method of claim 1 , wherein the pharmaceutical composition comprising CoQ10 is administered in the form of a CoQ10 cream at a dosage of CoQ10 between 0.01 mg/cm 2 and 5 mg/cm 2 .

16. The method of claim 1 , wherein the pharmaceutical composition comprising CoQ10 is administered with a second composition comprising an additional agent.

17. The method of claim 1 , wherein the pharmaceutical composition further comprises an additional agent.